Calcium Carbonate interactions
Full monograph for Calcium CarbonateCheck it against another medicine
Medicines
227 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Gefitinib | Major | Absorption | Coadministration with drugs that elevate gastric pH such as H2-receptor antagonists and antacids may decrease the plasma concentrations of gefitinib. According… | 5 sources — open the full entry |
| Selpercatinib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in… | 2 sources — open the full entry |
| Sotorasib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma. | 2 sources — open the full entry |
| Acalabrutinib | Moderate | Absorption | INTERVAL: Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of acalabrutinib and reduce its… | 2 sources — open the full entry |
| Alendronic acid | Moderate | Absorption | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to… | 9 sources — open the full entry |
| Alendronic Acid + Vitamin D3 | Moderate | Absorption | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to… | 9 sources — open the full entry |
| Amlodipine Besilate | Moderate | Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been… | 46 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Absorption · Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms | 53 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been… | 46 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Absorption · Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms | 50 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been… | 46 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been… | 46 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been… | 46 sources — open the full entry |
| Aspirin | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Atenolol | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Absorption · Synergy | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism…2 documented mechanisms | 22 sources — open the full entry |
| Atropine Sulfate (Injection) | Moderate | Absorption | INTERVAL: Concurrent administration of antacids or adsorbent antidiarrheal agents may decrease the oral bioavailability of atropine. | 1 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Baloxavir Marboxil | Moderate | Absorption | Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir. The proposed… | 3 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Absorption · Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism…2 documented mechanisms | 11 sources — open the full entry |
| Betaxolol Hydrochloride | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Bimatoprost + Timolol | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Bisacodyl | Moderate | Absorption | INTERVAL: By increasing gastric pH, antacids may reduce the resistance of the enteric coating of bisacodyl tablets, resulting in earlier release of bisacodyl… | 1 sources — open the full entry |
| Bisoprolol Fumarate | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Absorption · Antagonism | Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been…2 documented mechanisms | 53 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Absorption · Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 22 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleate | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Brinzolamide + Timolol | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Carbonyl Iron + Folic Acid | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Carvedilol | Moderate | Absorption | INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism… | 7 sources — open the full entry |
| Cefditoren | Moderate | Absorption | Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil. | 2 sources — open the full entry |
| Cefpodoxime Proxetil | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefpodoxime Proxetil + Clavulanic Acid | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefuroxime Axetil | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Cefuroxime Axetil + Clavulanic Acid | Moderate | Absorption | INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime… | 4 sources — open the full entry |
| Ceritinib | Moderate | Absorption | Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been… | 2 sources — open the full entry |
| Cetalkonium Chloride + Choline Salicylate | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Absorption | INTERVAL: Concomitant administration of antacids or kaolin may reduce the oral bioavailability of chloroquine. The proposed mechanism is adsorption of… | 9 sources — open the full entry |
| Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 35 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
| Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
Food & lifestyle
bran
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
grain
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
rhubarb
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
spinach
ModerateAbsorption
Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.
What to do: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.
6 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Canadian Pharmacists Association "e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink" (2006):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Mangels AR "Bone nutrients for vegetarians." Am J Clin Nutr 100 (2014): epub
- Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8
Conditions
Conditions in which Calcium Carbonate needs care, as documented in this source.
Cardiac Conduction System Disease
MajorCalcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Hyperphosphatemia
MajorElevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Kidney Diseases
MajorAbsorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Malabsorption Syndromes
MajorCalcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.
2 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
Sarcoidosis
MajorHypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.
3 sources
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation (2001):
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):